RES can exhibit anti-CRC activity through the MAPK pathway, for example, by activating the P38-MAPK in a bone morphogenetic protein receptor (BMPR)-dependent manner (115), and can decrease CRC cell survival through the P38-MAPK/c-Myc pathway (22). Here, MYC is linked to colorectal carcinoma.